search
Back to results

Study of Oxycyte in Severe Closed Head Injury

Primary Purpose

Traumatic Brain Injury

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
perfluorocarbon emulsion (Oxycyte) infusion
Sponsored by
Tenax Therapeutics, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Traumatic Brain Injury focused on measuring Oxycyte, perfluorocarbon oxygen carrier, brain oxygen tension

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: severe closed head injury patients or GCS 3-9 patients who receive brain oxygen monitoring ventriculostomy/ICP monitor at least one reactive pupil no known life threatening disease prior to trauma age 18-70 years old consent for microdialysis/brain 02 monitoring legal family representative present that can give informed consent for perfluorocarbon administration Exclusion Criteria: no motor response both pupils fixed and dilated no consent available allergy to egg proteins coagulopathy major liver injury major pulmonary injury

Sites / Locations

  • Virginia Commonwealth University Medical Center

Outcomes

Primary Outcome Measures

Increase in Brain Oxygen Tension levels in severe traumatic head injury patients with GCS score of 3-9

Secondary Outcome Measures

Adverse events will be captured throughout drug infusion and 2 weeks post, Severe adverse events will be captured for 6 months. Glascow outcomes score at 3 and 6 months

Full Information

First Posted
September 9, 2005
Last Updated
June 9, 2011
Sponsor
Tenax Therapeutics, Inc.
Collaborators
Virginia Commonwealth University
search

1. Study Identification

Unique Protocol Identification Number
NCT00174980
Brief Title
Study of Oxycyte in Severe Closed Head Injury
Official Title
An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002
Study Type
Interventional

2. Study Status

Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Tenax Therapeutics, Inc.
Collaborators
Virginia Commonwealth University

4. Oversight

5. Study Description

Brief Summary
Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in better brain oxygen consumption, less cell death, and better functional outcome. This study will test the hypothesis that Oxycyte is an effective way to increase brain oxygen levels in severe head injury.
Detailed Description
Decreased brain oxygen in severe brain injuries appears to be implicated in poor functional outcome and death. Animal and clinical studies have shown that increasing brain oxygen in such patients improves functional outcome, and Oxycyte has been shown to be an effective means of delivering oxygen to tissues, including the brain. This study is an eight patient proof of concept study to test the effects of oxygen delivery with Oxycyte in patients with a severe traumatic head injury with a Glasgow Coma Scale (GCS) score of 3 to 9. Subjects diagnosed with a severe head injury (GCS 3-9) who receive a brain oxygen monitor and microdialysis catheter, will undergo baseline monitoring for 4 hours. In the first 4 subjects the Fi02 on the ventilator will be increased to 50% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 50% for 24 hours. In the second 4 subjects the Fi02 on the ventilator will be increased to 100% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 100% for 24 hours. Subjects will be enrolled, treated, and then monitored by LICOX 02 monitor before and after infusion of PFC, and then for at least 48 hours following the discontinuation of Oxycyte.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury
Keywords
Oxycyte, perfluorocarbon oxygen carrier, brain oxygen tension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
perfluorocarbon emulsion (Oxycyte) infusion
Other Intervention Name(s)
Oxycyte
Intervention Description
one time dose of 3mL/kg over 15 minutes
Primary Outcome Measure Information:
Title
Increase in Brain Oxygen Tension levels in severe traumatic head injury patients with GCS score of 3-9
Secondary Outcome Measure Information:
Title
Adverse events will be captured throughout drug infusion and 2 weeks post, Severe adverse events will be captured for 6 months. Glascow outcomes score at 3 and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: severe closed head injury patients or GCS 3-9 patients who receive brain oxygen monitoring ventriculostomy/ICP monitor at least one reactive pupil no known life threatening disease prior to trauma age 18-70 years old consent for microdialysis/brain 02 monitoring legal family representative present that can give informed consent for perfluorocarbon administration Exclusion Criteria: no motor response both pupils fixed and dilated no consent available allergy to egg proteins coagulopathy major liver injury major pulmonary injury
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M. R Bullock, M.D.
Organizational Affiliation
Virginia Commonwealth University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Virginia Commonwealth University Medical Center
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of Oxycyte in Severe Closed Head Injury

We'll reach out to this number within 24 hrs